LONG-TERM RESULTS OF PORCINE BIOPROSTHESES IN THE TRICUSPID POSITION

被引：16

作者：

JEGADEN, O

PERINETTI, M

BARTHELET, M

VEDRINNE, C

DELAHAYE, F

MONTAGNA, P

MIKAELOFF, PH

机构：

[1] Department of Cardiac Surgery, Cardiovascular and Pneumologic Hospital, Lyon

来源：

EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY | 1992年 / 6卷 / 05期

关键词：

TRICUSPID VALVE REPLACEMENT; BIOPROSTHESIS;

D O I：

10.1016/1010-7940(92)90108-A

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Between 1974 and 1990, 58 patients underwent tricuspid valve replacement with porcine bioprostheses (Hancock 42, Carpentier-Edwards 16) during multiple valve replacement (double, 21; triple, 37). Perioperative mortality was 12%; 16 patients died later, mostly from cardiac causes. Actuarial survival (1 patient lost to follow-up) was 81% +/- 11% at 5 years, and 60% +/- 17% at 10 years. Reoperation because of Hancock prosthesis deterioration was performed in 2 patients at 11 and 15 years, respectively. At last follow-up (mean 108 +/- 48 months), 82% of survivors (28/34) were functionally improved. Doppler echocardiography was performed in 29 patients in February 1991. In 21 patients, after 88 +/- 40 months of follow-up, the bioprosthesis was normal, there was no leaflet malformation, no significant tricuspid regurgitation and the mean diastolic transprosthetic gradient (DTPG) was 3.8 +/- 1.7 mm Hg. In 7 patients (follow-up: 129 +/- 40 months, P < 0.05), there was moderate dysfunction (all Hancock prostheses) with leaflet sclerosis, tricuspid regurgitation grade 2, and mean DTPG 5.7 +/- 1.8 mm Hg (P < 0.05). Only 1 patient (Hancock prosthesis implanted in 1981) had severe tricuspid prosthesis stenosis with very thickened leaflets and mean DTPG 13 mm Hg. Pulmonary artery hypertension (most often fixed) was present in 11 patients, associated with a poor functional result and a significantly higher DTPG. We conclude that porcine bioprostheses in tricuspid position have an acceptable long-term durability and satisfactory performance. Prosthetic dysfunction correlates with the length of follow-up of patients and with the presence of fixed pulmonary artery hypertension.

引用

页码：256 / 260

页数：5

共 21 条

[1] Baughman K.L., Kallman C.H., Yurchak P.M., Daggett W.M., Buckley M.J., Predictors of survival after tricuspid valve surgery, Am J Cardiol, 54, pp. 137-141, (1984)
[2] Bortolotti U., Milano A., Guerra F., Mazzucco A., Mossuto E., Thiene G., Gallucci V., Failure of Hancock pericardial xenografts: Is prophylactic bioprosthetic replacement justified?, Ann Thorac Surg, 51, pp. 430-437, (1991)
[3] Bowen T.E., Tri T.B., Wortham D.C., Thrombosis of a St. Jude Medical tricuspid prosthesis. Case Report, J Thorac Cardiovasc Surg, 82, pp. 257-262, (1981)
[4] Carpentier A., Deloche A., Hanania G., Forman J., Sellier P., Piwnica A., Dubost C., Surgical management of acquired tricuspid valve disease, J Thorac Cardiovasc Surg, 67, pp. 53-65, (1974)
[5] Cohen S.R., Sell J.E., McIntosh C.L., Clark R.E., Tricuspid regurgitation in patients with acquired, chronic, pure mitral regurgitation - II nonoperative management, tricuspid valve annuloplasty, and tricuspid valve replacement, J Thorac Cardiovasc Surg, 94, pp. 488-497, (1987)
[6] Coll-Mazzei J.V., Jegaden O., Janody P., Rumolo A., Bonnefoy J.Y., Mikaeloff P., Results of triple valve replacement: Perioperative mortality and long term results, J Cardiovasc Surg, 28, pp. 369-373, (1987)
[7] Del Campo C., Alkalin H., McKenzie F.N., Evaluation of the Carpentier-Edwards porcine bioprosthesis in the tricuspid position, Texas Heart Inst J, 9, pp. 299-302, (1982)
[8] Foster A.H., Greenberg G.J., Underhill D.J., McIntosh C.L., Clark R.E., Intrinsic failure of Hancock mitral bioprostheses: 10- to 15-year experience, Ann Thorac Surg, 44, pp. 568-577, (1987)
[9] Guerra F., Bortolotti U., Thiene G., Milano A., Mazzucco A., Talenti E., Stellin G., Gallucci V., Long-term performance of the Hancock porcine bioprosthesis in the tricuspid position. A review of forty-five patients with fourteen-year follow-up, J Thorac Cardiovasc Surg, 99, pp. 838-845, (1990)
[10] Jegaden O., Girard C., Finet G., Bouvier H., Vial C., Montagna P., Rumolo A., Mikaeloff P., Myocardial protection with Hamburg oxygenated crystalloid cardioplegic solution for multiple coronary bypass and multi valvular replacement, J Cardiovasc Surg, 32, pp. 233-238, (1991)

← 1 2 3 →